Abstract:PURPOSE: To further confirm the benifit of front-line use of all-trans retinoic acid (ATRA) combined with arsenic trioxide (As2O3) in patients with newly diagnosed acute promyelocytic leukemia (APL), we observed the long-term survival of the current group (median follow-up: 48 months) and compared it with our historical control. PATIENTS AND METHODS: There were two groups of patients with newly diagnosed APL enrolled in this analysis. The current cohort of patients includes 60 patients since April 2001. The historical cohort of patients included 56 patients from May 1998 to March 2001. No statistically significant differences were found between these two groups in terms of clinical characteristics including sex and age distribution or hematological data before treatment. For the current cohort of patients, all patients received 25mg/m2 ATRA orally and 0.16mg/kg As2O3 intravenously per day till CR. Once CR achieved, they were given 3 courses of consolidation chemotherapy and then 5 cycles of sequential treatment of ATRA, As2O3 and 6-MP/MTX. For the historical group, ATRA was given either 25mg/m2 daily till CR, chemotherapy was added in case of leukocytosis. The post-remission therapy consists of chemotherapy with or without ATRA. Quantitative real-time reverse transcription-polymerase chain reaction (RQ-RT-PCR) measurements of PML-RARa mRNA were retrospectively assessed before treatment, after CR, after consolidation, after maintenance and during follow-up period. The efficacy of these two protocol in terms of remission induction, molecular response and long-term survival were compared with our historical control. RESULT: In the current group, 56 (93.3%) patients achieved CR, and the median time to CR was 27 days. Compared with the historical group, the combined therapy induced an early hematological response. Till the last follow-up at April 2006, two patients underwent extramedullary relapse, one of them also relapsed in marrow thereafter, one patient died from CNS leukemia, and all the other patients were alive and remained in hematological remission. With a median follow-up of 48 months (25 to 60 months), the 4-year OS and EFS was estimated 98.1%±1.8% and 94.2%±3.3%. For the historical group, after a median follow-up of 56 months (12 to 79 months), the 4-year OS and EFS was estimated 83.4%±5.4% (P=0.012) and 45.6%±7.6% (P<0.00001). For the current group, PML-RARa normalized dose was more significantly decreased after remission induction and after consolidation as compared with the historical cohort. In the last follow-up, all of the available event-free patients of the current group remain in molecular remission (PML-RARa DoseN undetectable). CONCLUSION: These 4-year data of follow-up demonstated a benefit of front-line combination of ATRA and As2O3 regarding long-term survival (OS or EFS) of patients with newly diagnosed APL. With prolonged follow-up, we might be able to find a better chance of curing the disease.

[A Serial Study of in Cytogenetic Change and Morphology on the Tetra-Arsenic Tetra-Sulfide Treatment in Untreated or Recurrent Acute Promyelocytic Leukemia].

Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy

Long-Term Efficacy of Low-Dose All-Trans Retinoic Acid Plus Individually Adapted Chemotherapy Induction Followed by Arsenic Trioxide Based Post-Remission Therapy in Adults with Newly Diagnosed Acute Promyelocytic Leukemia

The Clinical Efficacy of All-Trans Retinoic Acid Plus Arsenic Trioxide in 177 Newly Diagnosed Acute Promyelocytic Leukemia Patients

Prognosis Influence of Additional Chromosome Abnormalities in Newly Diagnosed Acute Promyelocytic Leukemia with T(15;17)(q24;q21)

Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy.

Long-Term Efficacy Of Low-Dose All-Trans Retinoic Acid Plus Minimal Chemotherapy Induction Followed By The Addition Of Intravenous Arsenic Trioxide Post-Remission Therapy In Newly Diagnosed Acute Promyelocytic Leukaemia

Treatment of Acute Promyelocytic Leukemia with ATRA and As2O3: a Model of Molecular Target-Based Cancer Therapy.

Comparative Proteome Study of Apoptosis Induced by As4S4 in Retinoid Acid Resistant Human Acute Promyelocytic Leukemia NB4-R1 Cells

Tetra-Arsenic Tetra-Sulfide For The Treatment Of Acute Promyelocytic Leukemia: A Pilot Report

[Change of PML/PML-RARalpha Protein During Treatment with Tetraarsenic Tetrasulfide (as4s4) in Patients with Acute Promyelocytic Leukemia].

[Effect of Additional Chromosome Abnormalities on the Outcome of Newly Diagnosed Acute Promyelocytic Leukemia Treated with Red Arsenic Sulfide and All Trans-Retinoic Acid Plus Anthracyclin Based Protocol].

Clinical analysis of patients with therapy-related acute promyelocytic leukemia patients

An Analysis about the Curative effect of the Sequential Therapy Consisting of All-trans Retinoic Acid, Arsenic Trioxide and Chemotherapy for Acute Promyelocytic Leukemia

[Can As2O3 Improve the Prognosis of Childhood Acute Promyelocytic Leukemia?--a Single Center Experience].

Clinical Observation on the Efficacy of All-Trans Retinoic Acid (atra) Combined with Arsenic Trioxide (as2o3) in Newly Diagnosed Acute Promyelocytic Leukemia (Apl).

Long-Term Survival And Prognostic Study In Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid, Chemotherapy, And As2o3: An Experience Of 120 Patients At A Single Institution

Long-Term Follow-Up Confirms the Benefit of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (as2o3) As Front Line Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.

A Model of Molecular Target-Based Cancer Therapy

Long-Term Efficacy and Safety of All-Trans Retinoic Acid/Arsenic Trioxide-Based Therapy in Newly Diagnosed Acute Promyelocytic Leukemia